Anti-Chromogranin A / CHGA, clone MSVA-380R

Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide. CHGA antibody recognizes Chromogranin A, a secretory glycoprotein encoded by the CHGA gene and widely expressed in neuroendocrine cells. CHGA Antibody for IHC (clone MSVA-380R) is a recombinant rabbit monoclonal antibody developed for immunohistochemical detection of this hallmark neuroendocrine marker in formalin-fixed, paraffin-embedded tissues. Chromogranin A localizes predominantly to the cytoplasm within dense-core secretory granules of endocrine and neuroendocrine cells, where it participates in hormone storage, granule biogenesis, and regulated secretion. This CHGA antibody is part of a broader Chromogranin A antibody panel offered by NSJ Bioreagents.CHGA antibody, also referred to as Chromogranin A antibody and CgA antibody in the literature, targets a member of the granin family of acidic secretory proteins. Chromogranin A is synthesized as a precursor protein that undergoes proteolytic processing to generate several bioactive peptides, including vasostatin, pancreastatin, and catestatin. These peptides contribute to regulation of hormone release, cardiovascular function, and metabolic signaling pathways. Within secretory granules, Chromogranin A plays an essential structural role by promoting aggregation of peptide hormones and stabilizing granule formation in the trans-Golgi network.CHGA expression is characteristic of neuroendocrine tissues such as adrenal medulla, pancreatic islets, gastrointestinal enteroendocrine cells, parathyroid gland, and various dispersed neuroendocrine cell populations throughout the respiratory and genitourinary tracts. Cytoplasmic granular staining is the expected immunohistochemical pattern in these cell types. Because of this restricted lineage distribution, Chromogranin A is widely used in research studies as a robust marker of neuroendocrine differentiation.In tumor biology, CHGA expression is frequently evaluated in neuroendocrine neoplasms including carcinoid tumors, pancreatic neuroendocrine tumors, small cell carcinoma, medullary thyroid carcinoma, and pheochromocytoma. Strong cytoplasmic granular staining supports neuroendocrine lineage, while most non-neuroendocrine carcinomas lack expression. CHGA antibody for IHC is therefore commonly incorporated into research panels investigating neuroendocrine differentiation and tumor classification.The recombinant rabbit monoclonal clone MSVA-380R provides consistent detection of Chromogranin A expression patterns in normal and neoplastic neuroendocrine tissues for research use at NSJ Bioreagents.This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.